What share buyback actions did Fresenius Medical Care (FMS) take in 2026?

Fresenius Medical Care cancelled 24.8 million repurchased shares, reducing share capital by 8.5%, and launched a second buyback of around EUR 1 billion. According to the company, the new program runs in tranches within 12 months, with 2,454,945 shares bought by June 30, 2026.

Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Fresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 1% year-on-year (+5% organic) with growth in all operating segments. Operating income rose 10% to EUR 466 million, while operating income excluding special items increased 20% to EUR 569 million, expanding the margin2 to 11.7%.

Net income declined 3% to EUR 218 million, but net income excluding special items grew 13% to EUR 303 million. Basic EPS increased 6% to EUR 0.81, and EPS excluding special items rose 24% to EUR 1.13, supported by share buybacks. Operating cash flow grew 11% to EUR 860 million; free cash flow was stable at EUR 625 million.

The FME25+ program delivered EUR 67 million additional sustainable savings in Q2, with around 100 U.S. clinics exited and related EUR 42 million special costs. The company cancelled 24.8 million shares (8.5% of capital) and began a second buyback of about EUR 1 billion. Fresenius Medical Care reaffirmed its 2026 outlook for broadly flat revenue and operating income2 within a mid-single digit range at constant currency, excluding special items.

Positive

Organic revenue growth 5% in Q2 2026 with all segments contributing
Operating income excl. special items +20% in Q2; margin2 up to 11.7%
EPS excl. special items +24% in Q2 2026 to EUR 1.13
Operating cash flow +11% in Q2 to EUR 860 million; +16% in H1
Share buybacks cancelled 24.8 million shares (8.5% of capital) and launched ~EUR 1 billion new program
FME25+ savings EUR 67 million in Q2; target EUR 250 million in 2026 and EUR 1.2 billion by end of 2027

Negative

Reported net income -3% in Q2 2026 and -11% in H1 year-on-year
Group revenue H1 2026 -2% year-on-year despite positive constant-currency growth
Clinic footprint optimization included exiting around 100 U.S. dialysis clinics in 2026
Special items include EUR 71 million impact related to TAVNEOS marketing authorization revocation
Total net debt and lease liabilities increased 6% year-on-year to EUR 9,902 million

News Explained

By June 30, the second buyback had repurchased 0.9% of issued shares for EUR94 million, while net debt and leases stood at EUR9,902 million.

The company’s second share-buyback program had moved from announcement to execution: by June 30, it had repurchased 2,454,945 shares, representing 0.9% of issued shares, for EUR94 million.

The U.S. 5008X CAREsystem rollout had reached 227 clinics and more than 600,000 treatments; around 10% of U.S. clinic dialysis machines had been replaced, against a full-year target of around 20%.

At June 30, total net debt and lease liabilities were EUR9,902 million, up 6% year on year, while net leverage was 2.6 times, around the lower end of the stated 2.5-to-3.0-times target band.

The first buyback tranche is planned to end on December 15, 2026; the broader approximately EUR1 billion program is being executed in tranches within 12 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/03/2026 - 02:20 PM

Organic revenue growth¹ of 5% with growth in all operating segments
Operating income² grew by 23%, resulting in further margin expansion to 11.7%
Reported operating income grew by 10% and reported net income³ decreased by 3%
Earnings per share² (EPS) increased by 28%, supported by the share buyback program
227 U.S. clinics converted to the 5008X CAREsystem with more than 600,000 treatments⁴
Reaffirms FY 2026 outlook

BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered another quarter of highly profitable growth, driven by solid organic revenue growth and improved profitability," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Care Delivery achieved strong operating income² growth. Importantly, underlying operating income² improved by 34% excluding the positive TDAPA effects, driven by rate improvements and benefits from revenue cycle management. The U.S. rollout of our innovative 5008X CAREsystem is progressing at speed, now available in 227 U.S. clinics, having performed more than 600,000 treatments. We are excited by the benefits we are seeing through early insights from our scientific research initiative BEACON-US and the potential for this therapy to significantly improve patient outcomes in the U.S.," Giza continued, "Operating income growth in the first half was in line with our planned phasing for the full year and we confirm our outlook for 2026. Through disciplined execution of the FME Reignite strategy, we are further improving the quality of patient care, investing in innovation and profitable future growth, addressing regulatory headwinds – creating long-term value for our shareholders."

Key figures Q2 and H1 2026 (unaudited)

	Q2 2026	Q2 2025	Growth	Growth	H1 2026	H1 2025	Growth	Growth
	EUR m	EUR m	yoy	yoy, cc	EUR m	EUR m	yoy	yoy, cc
Revenue	4,861	4,792	1 %	4 %	9,473	9,673	-2 %	3 %
Operating income	466	425	10 %	15 %	752	757	-1 %	5 %
excl. special items²	569	476	20 %	23 %	1,036	933	11 %	17 %
Net income³	218	225	-3 %	3 %	336	376	-11 %	-6 %
excl. special items²	303	268	13 %	17 %	553	514	8 %	13 %
Basic EPS (EUR)	0.81	0.77	6 %	13 %	1.24	1.28	-4 %	1 %
excl. special items²	1.13	0.91	24 %	28 %	2.04	1.75	16 %	22 %

yoy = year-on-year, cc = at constant currency, EPS = earnings per share

Progress on FME Reignite

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, continues the focused execution of its FME Reignite strategy. The strategy focuses on strengthening core operations, driving profitable growth and innovation, and advancing the company culture.

After initiating the large-scale launch of the innovative 5008X CAREsystem in the U.S. in early 2026, the upscaling of production at Care Enablement and accelerated machine replacement at Care Delivery is progressing at speed. By today, around 10% of dialysis machines in Fresenius Medical Care clinics in the U.S. were replaced by the new system, well on track for the full year target of around 20%. As more clinics transitioned to the 5008X CAREsystem, the number of performed treatments has increased to more than 600,000, thereof around 170,000 in HDF modality and already more than 100,000 in HVHDF modality. The early U.S. experience with HVHDF is encouraging, with many patients feeling better during and after dialysis – for example data showing 40% fewer muscle cramps. Early observations are tracking consistently with previously published international, randomized and real-world studies, including the landmark, EU-funded CONVINCE study, that collectively have associated HVHDF with fewer hospitalizations, fewer missed treatments, and improved survival outcomes compared with conventional hemodialysis.

During the second quarter of 2026, the FME25+ transformation program delivered EUR 67 million additional sustainable savings. Fresenius Medical Care successfully concluded the 2026 optimization plan of its U.S. dialysis clinic footprint by exiting around 100 clinics. The company retained the majority of its dialysis patients in neighboring clinics according to plan and expects the benefit of higher network efficiency to contribute to profitability in the second half of 2026. FME25+ one-time costs, including clinic closures cost, were treated as special items and amounted to EUR 42 million. The company expects EUR 250 million savings and EUR 350 million related one-time costs in 2026. FME25+ savings are expected to total EUR 1.2 billion by the end of 2027.

As part of the capital allocation framework, share buyback programs complement shareholder returns through dividends. Upon successful completion of the initial share buyback program on April 30, all 24.8 million repurchased shares were cancelled, thereby reducing the share capital by 8.5%. On May 26, a second program for a total volume of around EUR 1 billion (excluding ancillary costs) was announced and is being executed in tranches within 12 months. The first tranche was initiated on May 28 and is planned to end by December 15, 2026. As of June 30, 2,454,945 shares or 0.9% of total issued shares have been repurchased for a total investment amount of EUR 94 million.

Solid organic revenue growth driven by all operating segments

In the second quarter of 2026, Group revenue increased by 1% compared to prior year (+4% at constant currency, +5% organic¹) to EUR 4,861 million. Currency effects negatively impacted revenue development in all three operating segments. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development by 50 basis points.

Care Delivery revenue increased by 3% (+5% at constant currency, +7% organic¹) to EUR 3,478 million. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development by 90 basis points.

In Care Delivery U.S., revenue increased by 3% (+6% at constant currency, +7% organic¹) to EUR 2,897 million. TDAPA reimbursement regulations, favorable rate effects and lower implicit price concessions had a positive impact while exchange rates developed unfavorably. U.S. same market treatment growth came in at -0.9%.

In Care Delivery International, revenue increased by 3% (+5% at constant currency, +11% organic¹) to EUR 581 million, driven by positive organic growth¹. International same market treatment growth amounted to 0.8%.

Value-Based Care revenue increased by 6% (+9% at constant currency, +9% organic¹) to EUR 536 million. The development in the quarter was driven by a higher number of member months and a positive effect from premium rates, partially offset by the changed risk contracting for one of the contracts.

Care Enablement revenue increased by 2% (+3% at constant currency, +3% organic¹) to EUR 1,371 million. Positive pricing and volume development outside China, mainly driven by the sales of 5008X CAREsystem, were partly offset by negative impacts from volume-based procurement and stricter tender requirements in China.

Within Inter-segment eliminations⁵, revenue for services provided and products transferred between the operating segments at fair market value came in at negative EUR 524 million.

In the first half of 2026, Group revenue decreased by 2% (+3% at constant currency, +4% organic¹) to EUR 9,473 million. Significant currency effects negatively impacted revenue development in all three operating segments. Divestitures realized as part of the portfolio optimization plan negatively impacted the revenue development by 50 basis points. Care Delivery revenue decreased by 1% (+5% at constant currency, +7% organic¹) to EUR 6,772 million, with Care Delivery U.S. decreased by 1% (+6% at constant currency, +7% organic¹) to EUR 5,662 million and Care Delivery International decreasing by 1% (+2% at constant currency, +7% organic¹) to EUR 1,110 million. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development of Care Delivery by 90 basis points and the revenue development of Care Delivery International by 4,700 basis points. U.S. same market treatment growth came in at -0.6% while international same market treatment growth amounted to 1.1%. Value-Based Care revenue decreased by 1% (+6% at constant currency, +6% organic¹) to EUR 1,027 million. Care Enablement revenue decreased by 2% (+2% at constant currency, +2% organic¹) to EUR 2,670 million. Inter-segment eliminations came in at negative EUR 996 million.

Significant earnings growth and margin expansion

In the second quarter of 2026, Group operating income increased by 10% (+15% at constant currency) to EUR 466 million, resulting in a margin of 9.6% (Q2 2025: 8.9%). Operating income excluding special items significantly increased by 20% (+23% at constant currency) to EUR 569 million, resulting in a margin² of 11.7% (Q2 2025: 9.9%).

Operating income in Care Delivery increased by 26% (+33% at constant currency) to EUR 435 million, resulting in a margin of 12.5% (Q2 2025: 10.2%). Operating income excluding special items significantly increased by 40% (+45% at constant currency) to EUR 527 million, resulting in a margin² of 15.1% (Q2 2025: 11.2%). Compared to previous year, the strong improvement was driven by positive rate effects, a positive impact from TDAPA reimbursement regulations as well as savings from the FME25+ program. Special items include EUR 71 million impacts from the recommended revocation of the TAVNEOS® marketing authorization which led primarily to an impairment of intangible assets recorded by Vifor Fresenius Medical Care Renal Pharma Ltd., resulting in a negative impact on FME AG's income from equity method investees.

Operating income in Value-Based Care improved to EUR 17 million, compared to a loss of EUR 9 million in the prior year, resulting in a margin of 3.2% (Q2 2025: -1.7%) Operating income excluding special items improved to EUR 18 million compared to a loss of EUR 9 million in the prior year, resulting in a margin² of 3.3% (Q2 2025: -1.7%) and reflecting the quarterly earnings volatility, which is inherent to the business model. The improvement was driven by an enhanced savings rate and positive contributions from the FME25+ program.

Operating income in Care Enablement increased by 11% (+12% at constant currency) to EUR 99 million, resulting in a margin of 7.2% (Q2 2025: 6.6%). Operating income excluding special items decreased by 6% (-5% at constant currency) to EUR 111 million, resulting in a margin² of 8.1% (Q2 2025: 8.7%). Compared to the previous year's quarter, positive contributions from FME25+ program, the increased sales of 5008X CAREsystem as well as positive price and volume effects outside China contributed positively. This was offset mainly by inflationary cost increases as well as negative impacts from volume-based procurement and stricter tender requirements in China.

Operating income for Corporate amounted to a loss of EUR 46 million (Q2 2025: gain of EUR 7 million). Operating income excluding special items amounted to a loss of EUR 48 million (Q2 2025: loss of EUR 2 million). The development was mainly driven by the impacts from virtual power purchase agreements and the planned cost of the strategic IT platform investments.

In the first half of 2026, Group operating income decreased by 1% (+5% at constant currency) to EUR 752 million, resulting in a margin of 7.9% (H1 2025: 7.8%). Operating income excluding special items increased by 11% (+17% at constant currency) to EUR 1,036 million, resulting in a margin² of 10.9% (H1 2025: 9.6%). In Care Delivery, operating income increased by 6% (+16% at constant currency) to EUR 706 million, resulting in a margin of 10.4% (H1 2025: 9.8%). Operating income excluding special items significantly increased by 26% (+36% at constant currency) to EUR 924 million, resulting in a margin² of 13.6% (H1 2025: 10.7%). In Value-Based Care operating income improved to EUR 6 million compared to a loss of EUR 6 million in the prior year, resulting in a margin of 0.6% (H1 2025: -0.5%). Operating income excluding special items improved to EUR 26 million compared to a loss of EUR 5 million in the prior year, resulting in a margin²of 2.6% (H1 2025: -0.5%). In Care Enablement, operating income increased by 1% (+1% at constant currency) to EUR 186 million, resulting in a margin of 7.0% (H1 2025: 6.8%). Operating income excluding special items decreased by 3% (-2% at constant currency) to EUR 224 million, resulting in a margin² of 8.4% (H1 2025: 8.5%). Operating income for Corporate amounted to a loss of EUR 85 million (H1 2025: loss of EUR 74 million). Operating income excluding special items amounted to a loss of EUR 77 million (H1 2025: loss of EUR 15 million).

Net income³ decreased by 3% compared to prior year (+3% at constant currency) to EUR 218 million in the second quarter of 2026. Net income excluding special items increased by 13% (+17% at constant currency) to EUR 303 million.

In the first half of 2026, net income³decreased by 11% (-6% at constant currency) to EUR 336 million. Net income excluding special items increased by 8% (+13% at constant currency) to EUR 553 million.

Basic earnings per share (EPS) increased by 6% compared to prior year (+13% at constant currency) to EUR 0.81 in the second quarter of 2026, based on 268,438,292 shares. Basic EPS excluding special items increased by 24% (+28% at constant currency) to EUR 1.13.

In the first half of 2026, basic EPS decreased by 4% (+1% at constant currency) to EUR 1.24, based on 271,823,512 shares. Basic EPS excluding special items increased by 16% (+22% at constant currency) to EUR 2.04.

Strong operating cash flow, net leverage ratio stable around lower end of target corridor

In the second quarter of 2026, operating cash flow increased by 11% to EUR 860 million (Q2 2025: EUR 775 million), resulting in a margin of 17.7% (Q2 2025: 16.2%). In the first half of 2026, operating cash flow improved by 16% to EUR 1,087 million (H1 2025: EUR 938 million). The related margin came in at 11.5% (H1 2025: 9.7%). Both developments were mainly driven by favorable working capital development.

Free cash flow⁶ remained stable at EUR 625 million in the second quarter of 2026 (Q2 2025: EUR 628 million), resulting in a margin of 12.9% (Q2 2025: 13.1%). In the first half of 2026, Fresenius Medical Care increased free cash flow by 2% to EUR 665 million (H1 2025: EUR 649 million), resulting in a margin of 7.0% (H1 2025: 6.7%).

Total net debt and lease liabilities increased by 6% to EUR 9,902 million (Q2 2025: EUR 9,315 million). The net leverage ratio (net debt/EBITDA) remained stable at 2.6x in Q2 2026 (Q1 2026: 2.6x) and continues to be around the lower end of our 2.5x to 3.0x target band.

Patients, clinics and employees

As of June 30, 2026, Fresenius Medical Care treated 289,610 patients in 3,513 dialysis clinics worldwide and had 107,226 employees globally.

Outlook 2026 reaffirmed

In 2026, Fresenius Medical Care expects revenue growth¹ to be broadly flat compared to prior year. The company expects operating income² to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year.

The expected growth rates for 2026 are at constant currency and excluding special items in operating income. The 2025 basis for the revenue outlook is EUR 19,628 million and for the operating income outlook is EUR 2,212 million.

Investor conference call

Fresenius Medical Care will host a conference call for analysts and investors to discuss the results of the second quarter, on August 4, 2026, at 10 a.m. CEST / 4:00 a.m. EDT. Details are available on the Fresenius Medical Care website in the "Investors" section. A replay and a transcript will be available shortly after the call.

Please refer to our statement of earnings included at the end of this press release and to the attachments as separate PDF files for a complete overview of the results of the second quarter of 2026. Our form 6-K disclosure provides more details.

About Fresenius Medical Care:

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,513 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).

¹	At constant currency, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days
²	Adjusted for special items; growth rate at constant currency (if not stated otherwise); for further details please see the reconciliation attached to the press release
³	Net income attributable to shareholders of Fresenius Medical Care AG
⁴	Data as of July 24, 2026
⁵	The company transfers products from the Care Enablement segment to the Care Delivery segment at fair market value. Services provided by the Care Delivery segment for patients managed under the Value-Based Care segment are also provided at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within "Inter-segment eliminations".
⁶	Net cash provided by / used in operating activities, after capital expenditures, before acquisitions, investments, and dividends

Statement of earnings
	Three months ended June 30,
in € million, except share data, unaudited	2026	2025	Change	Change at cc

Revenue	4,861	4,792	1.4 %	3.6 %

Costs of revenue	3,551	3,577	-0.7 %	1.3 %
Selling, general and administrative expense	736	792	-7.1 %	-5.8 %
Research and development expense	40	38	4.0 %	4.9 %
(Income) loss from equity method investees	41	(45)	n.a.	n.a.
Other operating income	(208)	(343)	-39.5 %	-39.3 %
Other operating expense	235	348	-32.3 %	-33.5 %
Operating income	466	425	9.5 %	15.3 %
Operating income excl. special items¹	569	476	19.6 %	23.5 %

Interest expense, net	83	75	10.9 %	12.3 %
Income before taxes	383	350	9.3 %	15.9 %
Income tax expense	90	78	14.8 %	22.2 %
Net income	293	272	7.7 %	14.1 %
Net income attributable to noncontrolling interests	75	47	59.0 %	65.6 %
Net income²	218	225	-3.1 %	3.4 %
Net income² excl. special items¹	303	268	13.1 %	16.8 %

Weighted average number of shares	268,438,292	293,413,449

Basic earnings per share	€0.81	€0.77	6.0 %	13.0 %
Basic earnings per share excl. special items¹	€1.13	€0.91	23.6 %	27.7 %

In percent of revenue
Operating income margin	9.6 %	8.9 %
Operating income margin excl. special items¹	11.7 %	9.9 %

¹ For a reconciliation of special items, please refer to the table at the end of the press release.
² Attributable to shareholders of FME AG.

Statement of earnings
	Six months ended June 30,
in € million, except share data, unaudited	2026	2025	Change	Change at cc

Revenue	9,473	9,673	-2.1 %	3.3 %

Costs of revenue	6,983	7,275	-4.0 %	1.5 %
Selling, general and administrative expense	1,485	1,543	-3.7 %	0.8 %
Research and development expense	78	82	-4.5 %	-1.7 %
(Income) loss from equity method investees	0	(93)	-99.9 %	-99.9 %
Other operating income	(366)	(484)	-24.4 %	-23.5 %
Other operating expense	541	593	-9.1 %	-6.3 %
Operating income	752	757	-0.6 %	4.6 %
Operating income excl. special items¹	1,036	933	11.1 %	16.8 %

Interest expense, net	162	155	3.9 %	9.0 %
Income before taxes	590	602	-1.8 %	3.4 %
Income tax expense	133	139	-4.8 %	-0.1 %
Net income	457	463	-0.9 %	4.5 %
Net income attributable to noncontrolling interests	121	87	42.9 %	52.6 %
Net income²	336	376	-10.8 %	-6.4 %
Net income² excl. special items¹	553	514	7.6 %	12.8 %

Weighted average number of shares	271,823,512	293,413,449

Basic earnings per share	€1.24	€1.28	-3.7 %	1.0 %
Basic earnings per share excl. special items¹	€2.04	€1.75	16.2 %	21.8 %

In percent of revenue
Operating income margin	7.9 %	7.8 %
Operating income margin excl. special items¹	10.9 %	9.6 %

¹ For a reconciliation of special items, please refer to the table at the end of the press release.
² Attributable to shareholders of FME AG.

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company´s outlook

	Three months ended June 30,		Six months ended June 30,
in € million, unaudited	2026	2025	2026	2025

Operating performance excl. special items
These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items.

Revenue	4,861	4,792	9,473	9,673

Operating income	466	425	752	757
FME25+ Program	42	53	208	80
Legacy Portfolio Optimization¹	(3)	6	9	30
Legal Form Conversion Costs	—	1	—	1
Humacyte Remeasurements	(7)	(9)	(4)	65
Tavneos Impacts²	71	—	71	—
Sum of special items	103	51	284	176
Operating income excl. special items	569	476	1,036	933

Net income³	218	225	336	376
FME25+ Program	31	39	155	59
Legacy Portfolio Optimization¹	(9)	10	(2)	29
Legal Form Conversion Costs	—	1	—	1
Humacyte Remeasurements	(4)	(7)	(3)	49
Tavneos Impacts²	67	—	67	—
Sum of special items	85	43	217	138
Net income³ excl. special items	303	268	553	514

¹2026: mainly related to costs associated with the 2025 divestiture of select assets of FME AG's wholly owned Spectra Laboratories; 2025: mainly related to the proposed divestiture of select assets of FME AG's wholly owned Spectra Laboratories as well as the proposed divestitures in Brazil, Kazakhstan and Malaysia as well as impairment losses primarily related to right-of-use assets.
² The impacts from the recommended revocation of the TAVNEOS® marketing authorization which led primarily to an impairment of intangible assets recorded by Vifor Fresenius Medical Care Renal Pharma Ltd., resulting in a negative impact on FME AG's income (loss) from equity method investees.
³ Attributable to shareholders of FME AG.

Media contact
Christine Peters
T +49 160 60 66 770
Christine.Peters@FreseniusMedicalCare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
Dominik.Heger@FreseniusMedicalCare.com

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-accelerates-income-growth-to-23-in-the-second-quarter-of-2026-while-advancing-its-strategic-agenda-302841447.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

How did Fresenius Medical Care (FMS) perform financially in Q2 2026?

Fresenius Medical Care reported Q2 2026 revenue of EUR 4,861 million, up 1%, and operating income of EUR 466 million, up 10%. According to the company, operating income excluding special items rose 20% to EUR 569 million, expanding the margin2 to 11.7% at constant currency.

What was Fresenius Medical Care’s EPS and net income in Q2 2026 (FMS)?

In Q2 2026, Fresenius Medical Care’s basic EPS increased 6% to EUR 0.81, while net income fell 3% to EUR 218 million. According to the company, EPS excluding special items rose 24% to EUR 1.13 and net income excluding special items grew 13% to EUR 303 million.

How is Fresenius Medical Care progressing with the 5008X CAREsystem rollout in the U.S.?

By Q2 2026, Fresenius Medical Care had introduced the 5008X CAREsystem in 227 U.S. clinics, performing over 600,000 treatments. According to the company, about 10% of U.S. clinic machines were replaced, with early HVHDF experience showing encouraging patient-reported benefits like fewer muscle cramps.

What is the 2026 outlook for Fresenius Medical Care (FMS) revenue and operating income?

For 2026, Fresenius Medical Care expects revenue growth to be broadly flat versus 2025 and operating income2 to stay around current levels. According to the company, operating income2 should fall within a positive to negative mid-single digit percent range at constant currency, excluding special items.

What savings and costs are expected from Fresenius Medical Care’s FME25+ program by 2027?

In 2026, Fresenius Medical Care expects EUR 250 million FME25+ savings and EUR 350 million one-time costs, including clinic closure expenses. According to the company, total FME25+ savings are projected to reach EUR 1.2 billion by the end of 2027, supporting profitability improvements.

How did Fresenius Medical Care’s cash flow and leverage develop in Q2 2026 (FMS)?

Operating cash flow increased 11% to EUR 860 million in Q2 2026, while free cash flow held at EUR 625 million. According to the company, total net debt and lease liabilities reached EUR 9,902 million, with the net leverage ratio stable at 2.6x, near the lower end of its 2.5x–3.0x target band.